Ensartinib was active and generally well tolerated in patients with Anaplastic lymphoma kinase non small cell lung cancer 1).

1)
Horn L, Infante JR, Reckamp KL, Blumenshein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA. Ensartinib (X-396) in ALK-positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res. 2018 Mar 21. pii: clincanres.2398.2017. doi: 10.1158/1078-0432.CCR-17-2398. [Epub ahead of print] PubMed PMID: 29563138.